Irizarry_2001_J.Neuropathol.Exp.Neurol_60_923

Reference

Title : Alzheimer disease therapeutics - Irizarry_2001_J.Neuropathol.Exp.Neurol_60_923
Author(s) : Irizarry MC , Hyman BT
Ref : J Neuropathol Experimental Neurology , 60 :923 , 2001
Abstract :

Alzheimer disease (AD) is characterized pathologically by cholinergic deficits, amyloid plaques, neurofibrillary tangles, gliosis, and neuronal and synaptic loss. The primary therapeutic approach that has arisen from the pathological analysis of AD brain has been cholinergic augmentation by cholinesterase inhibitors, which modestly improve cognitive function. Research on the underlying pathophysiological dysfunction have focussed on AD-specific processes such as amyloid precursor protein, tau, and cerebral apolipoprotein E metabolism, and more general neurodegenerative processes such as inflammation, oxidation, excitotoxicity, and apoptosis. Rational neuroprotective approaches have led to recent trials of estrogen, antioxidant and anti-inflammatory medications in AD, and to the development of anti-amyloid strategies for delaying progression or preventing development of AD.

PubMedSearch : Irizarry_2001_J.Neuropathol.Exp.Neurol_60_923
PubMedID: 11589422

Related information

Citations formats

Irizarry MC, Hyman BT (2001)
Alzheimer disease therapeutics
J Neuropathol Experimental Neurology 60 :923

Irizarry MC, Hyman BT (2001)
J Neuropathol Experimental Neurology 60 :923